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Despite several inconsistencies and methodological biases (1), the dopamine hypothesis (DH)
remains a popular topic in schizophrenia research. In its current version III, the DH asserts that
environmental stress and substance abuse, in interaction with a genetic susceptibility, lead to
dopamine dysregulation, and that increases in striatal presynaptic dopamine concentration causes
psychosis (or proneness to psychosis) through a process of aberrant salience to external stimuli
(2). Recently, Jauhar et al. (3) examined the putative role of striatal dopamine synthesis capacity
in patients with bipolar disorders with current or previous psychotic episode compared to patients
with first-episode schizophrenia and healthy controls. Though this study and similar others (for a
review, see (2)) may show an association between the dopaminergic system and psychosis, these
findings cannot provide convincing evidence in support of the DH due to several methodological
limitations. In the following we will outline these biases by using Jauhar et al. (3) as a benchmark
study. However, the same issues likewise apply to other highly cited original research on the DH
(e.g., (4, 5)).
IMPACT OF PRECEDING ANTIPSYCHOTIC MEDICATION
Jauhar et al. (3) included people who have taken antipsychotics at some point prior to the scan,
and some who were taking them at the time of the scan. Only just over half of the patients with
psychotic disorders were antipsychotic naïve (10 of 22 in the bipolar group and 11 of 16 in the
schizophrenia group), and results for this group are not presented separately. In another influential
study on the DH conducted by Howes et al. (4), only 3 of 7 patients (43%) with schizophrenia
were naïve to antipsychotic drugs before imaging, and in a study by McGowan et al. (5), all 16
patients with schizophrenia included in the study were acutely medicated with antipsychotics. This
is problematic, because antipsychotics have a profound impact on dopaminergic pathways. That is,
antipsychotics can cause progressive brain change (6), and neurobiological alterations have been
demonstrated in animals (7) and healthy volunteers (8). It is likely that there are “carry-over”
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effects, such that patients who are described as “drug-free”
but who have previous exposure cannot be assumed to have
unaltered dopaminergic functioning (1). In support of this notion
it has consistently been shown that use of psychotropic drugs
in general (9) and antipsychotic drugs in particular (10) may
persistently alter neurobiological functioning. Therefore, the
effects of current or previous antipsychotic treatment, and other
psychotropic drugs, cannot be easily ignored. Neurobiological
characteristics attributed to psychosis may be drug-induced. A
longitudinal study by Howes et al. (11) on striatal dopamine
synthesis capacity in persons at-risk of psychosis is one of the
few that enrolled antipsychotic naïve participants only and which
found a prospective association between dopamine function and
the subsequent onset of schizophrenia. However, as we will detail
below, even in research with antipsychotic naïve participants
there are several other limitations that question the validity of the
reported findings.
CONFOUNDING BY ENVIRONMENTAL
STRESS AND SUBSTANCE ABUSE
Psychotic disorders are significantly influenced by environmental
adversity, i.e., both acute and enduring stress, which in turn
may impact on neurobiology (12). For instance, there is evidence
that early-life poor parental care and acute psychological stress
alter mesolimbic dopamine release in healthy volunteers (13).
Substance abuse is another confounder, because it is frequent
in psychotic patients, relates to environmental adversity, and
interferes with the dopaminergic system (14). For instance,
childhood trauma may increase ventral striatal dopamine
responses to amphetamine use (15). The attentive reader will
notice that we cite the same work as evidence against the
DH that Howes and Kapur (2) refer to as supporting the
DH. This is so because according to the DH version III,
environmental stress and substance abuse increase striatal
dopamine concentration, which is assumed to cause psychosis.
We, likewise, acknowledge that substance abuse and stress
impacts, among others, on dopaminergic pathways, but in
contrast to Howes and Kapur (2) we disagree that striatal
dopamine levels cause psychosis (or proneness to psychosis).
Howes and Kapur (2) assume that dopamine dysfunction
is part of the causal pathway leading to psychosis, but it
is equally possible that the relationship between substance
abuse/stress and dopamine as well as between substance
abuse/stress and psychosis are independent processes, with
the former relationship confounding analysis of an association
between dopamine function and psychosis. Amphetamines, for
instance, not only affect dopamine, but catecholamine in general
and also serotonergic pathways (16), and the neurobiology
of stress involves many more mechanisms than simply
dopaminergic neurotransmission (17). Neuroinflammation and
endocannabinoid signaling may be important substrates of
the association between social stress and psychosis (18). In
consequence, unless we account for the various neurobiological
effects of substance abuse and environmental stress, we cannot
know whether striatal dopamine concentration is directly
and causally involved in psychosis or merely a spurious
correlate.
POWER FAILURE AND SAMPLING ERROR
The number of participants with psychotic disorders and healthy
controls in research on the DH is very small. The samples
in Jauhar et al. (3), which are among the largest to date,
comprised 22 patients with bipolar disorder, 16 patients with
schizophrenia, and 22 healthy controls. In comparison, Howes
et al. (4) included 24 patients with prodromal symptoms, 7
patients with schizophrenia, and 12 healthy controls, McGowan
et al. (5) enrolled 16 patients with schizophrenia and 12
healthy controls, and Howes et al. (11) included 29 healthy
controls, 9 at-risk persons who developed psychosis, and 15 at-
risk persons who did not develop psychosis. These very small
group sizes are a serious issue, because power failure does not
only yield false-negative results, but, more importantly, it also
produces inflated effect sizes and false-positive associations (19).
Assume, for instance, that you want to determine the mean
difference in IQ scores between men and women in a given
population. All else being equal, study 1 enrols 10 men and
10 women, whereas study 2 samples 100 each. Even without
proof it should be evident that, due to sampling error, the
sex difference estimated in the smaller study 1, compared to
study 2, is less accurate and more likely to be an over- or
underestimation of the true difference, if there is any at all
(for more details, see (19)). Because the underestimated and
statistically insignificant group difference is unlikely to get
published, it is the overestimated and statistically significant
effect that enters the scientific literature. This form of selective
reporting also explains why there are too many underpowered
studies with statistically significant results in the psychiatric
literature on brain volume abnormalities (20). These biases
are rarely, if ever, appreciated in neurobiological research, but
severely undermine the validity of neuroimaging studies on the
DH.
INADEQUATE COMPARATORS
There is potential bias associated with comparing extreme groups
such as healthy controls to inpatients with schizophrenia (21,
22). Healthy controls are hardly comparable to people who
have been admitted to hospital with acute psychosis. There
are likely to be differences with respect to childhood adversity,
socio-economic status, lifestyle (i.e., diet, exercise, substance
abuse) and general physical health, but research on the DH
typically matches controls to inpatients based on sex, age,
and ethnicity only. A more stringent comparison would be
to contrast patients with schizophrenia with patients who are
equally distressed but non-psychotic, such as for instance acutely
admitted patients with panic disorder or cluster C personality
disorders. In contrast to healthy controls, patients with acutely
distressing non-psychotic mental disorders are likely to be
more comparable in terms of personal history of adversity,
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psychosocial impairments, and current levels of acute arousal and
stress.
DISCONFIRMING EVIDENCE
There are two lines of evidence that challenge the DH. First,
according to a comprehensivemeta-analysis of randomized trials,
antipsychotic medication does not prevent the development of
schizophrenia in persons at ultra-high risk of psychosis (23).
If increased striatal dopamine concentration were a necessary
cause, then antipsychotic drugs should prevent the first onset
of manifest psychosis in at-risk persons. Second, Howes and
Kapur (2) state that if a psychopharmacological agent were to
be found, that does not act upon the dopaminergic system
and which effectively treats psychotic symptoms, then the DH
would be rejected immediately. Although we are not aware
of a drug that does not influence dopamine function at all,
the effect of clozapine on D2 receptors is small compared
to the effects of other antipsychotic agents. Specifically, its
D2 binding affinity (expressed via the inhibition dissociation
constant K i) is approximately 75 times less than risperidone
and 100 times less than haloperidol (24). An analysis of the
correlation between symptom reduction and the D2 dopamine
blocking properties of different antipsychotics revealed clozapine
to be an outlier (25). Yet clozapine is regarded as being as
effective (26) if not more effective (27) than other antipsychotic
agents. Therefore, it appears that clozapine’s mechanism of
action is largely independent of its effects on the dopamine
system, and probably derives from its widespread effects on
other neurotransmitter systems. Although these findings do
not definitely disconfirm the DH, they suggest that dopamine
function is neither a sufficient nor a necessary cause of
psychosis.
CONCLUSIONS
The commonly conducted experimental tests of the DH,
such as the F-dopa uptake studies, are inconclusive due to
several limitations. Larger sample sizes with antipsychotic naïve
participants, adequate control of possible confounders and
stringent comparators are necessary to provide a convincing
test of the DH. If possible, researchers should measure striatal
dopamine concentration before and after the onset of psychosis
and statistically control for important covariates such as a
person’s activity, diet, and substance use, which impact on various
neurobiological systems besides dopamine. Future work should
also examine how stress, with its complex and multi-factorial
brain mechanisms, may account for both striatal dopamine
concentration and the experience of psychotic symptoms.
Finally, the limitations outlined in this opinion paper also
apply to other targets of drug action. Simply shifting the
focus to another isolated neurotransmitter, such as for instance
histamine, and analyzing its action in complete disregard
of interactions between neurochemicals, complex neurological
signaling networks and functional feedback loops, will not
sufficiently advance our knowledge of the multiple, inter-related
neurobiological pathways underlying psychosis.
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